vs
亚盛医药集团（AAPG）与Aclaris Therapeutics, Inc.（ACRS）财务数据对比。点击上方公司名可切换其他公司
Aclaris Therapeutics, Inc.的季度营收约是亚盛医药集团的2.3倍（$1.3M vs $574.1K）
亚盛医药集团是一家全球性临床阶段生物技术企业，专注于开发用于治疗癌症、慢性病毒感染及衰老相关疾病的创新靶向药物，核心研发方向为靶向细胞凋亡通路的小分子药物，业务覆盖中、美等全球市场，致力于满足未被满足的临床需求。
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
AAPG vs ACRS — 直观对比
营收规模更大
ACRS
是对方的2.3倍
$574.1K
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $574.1K | $1.3M |
| 净利润 | — | $-19.8M |
| 毛利率 | — | 58.9% |
| 营业利润率 | — | -1755.5% |
| 净利率 | — | -1528.6% |
| 营收同比 | — | -85.9% |
| 净利润同比 | — | 79.5% |
| 每股收益（稀释后） | — | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAPGACRS
| Q4 25 | $574.1K | $1.3M | ||
| Q3 25 | — | $3.3M | ||
| Q2 25 | $32.6M | $1.8M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $9.2M | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $2.8M | ||
| Q1 24 | — | $2.4M |
净利润AAPGACRS
| Q4 25 | — | $-19.8M | ||
| Q3 25 | — | $-14.6M | ||
| Q2 25 | $11.4M | $-15.4M | ||
| Q1 25 | — | $-15.1M | ||
| Q4 24 | — | $-96.6M | ||
| Q3 24 | — | $-7.6M | ||
| Q2 24 | — | $-11.0M | ||
| Q1 24 | — | $-16.9M |
毛利率AAPGACRS
| Q4 25 | — | 58.9% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | 90.7% | 71.0% | ||
| Q1 25 | — | 65.2% | ||
| Q4 24 | — | 92.3% | ||
| Q3 24 | — | 85.0% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 66.3% |
营业利润率AAPGACRS
| Q4 25 | — | -1755.5% | ||
| Q3 25 | — | -519.8% | ||
| Q2 25 | — | -1035.9% | ||
| Q1 25 | — | -1242.9% | ||
| Q4 24 | — | -1082.3% | ||
| Q3 24 | — | -240.9% | ||
| Q2 24 | — | -464.7% | ||
| Q1 24 | — | -789.4% |
净利率AAPGACRS
| Q4 25 | — | -1528.6% | ||
| Q3 25 | — | -443.0% | ||
| Q2 25 | — | -868.3% | ||
| Q1 25 | — | -1036.8% | ||
| Q4 24 | — | -1048.3% | ||
| Q3 24 | — | -174.6% | ||
| Q2 24 | — | -397.2% | ||
| Q1 24 | — | -706.5% |
每股收益（稀释后）AAPGACRS
| Q4 25 | — | $-0.16 | ||
| Q3 25 | — | $-0.12 | ||
| Q2 25 | — | $-0.13 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $-1.21 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $20.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $103.1M |
| 总资产 | — | $160.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAPGACRS
| Q4 25 | — | $20.0M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | — | $25.4M | ||
| Q1 25 | — | $30.4M | ||
| Q4 24 | — | $24.6M | ||
| Q3 24 | — | $47.7M | ||
| Q2 24 | — | $22.8M | ||
| Q1 24 | — | $35.8M |
股东权益AAPGACRS
| Q4 25 | — | $103.1M | ||
| Q3 25 | — | $120.1M | ||
| Q2 25 | — | $131.7M | ||
| Q1 25 | — | $144.1M | ||
| Q4 24 | — | $155.6M | ||
| Q3 24 | — | $130.2M | ||
| Q2 24 | — | $133.8M | ||
| Q1 24 | — | $142.0M |
总资产AAPGACRS
| Q4 25 | — | $160.5M | ||
| Q3 25 | — | $175.5M | ||
| Q2 25 | — | $189.1M | ||
| Q1 25 | — | $198.1M | ||
| Q4 24 | — | $220.3M | ||
| Q3 24 | — | $182.4M | ||
| Q2 24 | — | $161.1M | ||
| Q1 24 | — | $174.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-13.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-13.2M |
| 自由现金流率自由现金流/营收 | — | -1015.8% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-47.2M |
8季度趋势，按日历期对齐
经营现金流AAPGACRS
| Q4 25 | — | $-13.1M | ||
| Q3 25 | — | $-10.9M | ||
| Q2 25 | — | $-10.0M | ||
| Q1 25 | — | $-13.1M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | — | $22.0M | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-20.8M |
自由现金流AAPGACRS
| Q4 25 | — | $-13.2M | ||
| Q3 25 | — | $-11.0M | ||
| Q2 25 | — | $-10.0M | ||
| Q1 25 | — | $-13.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-12.3M | ||
| Q1 24 | — | $-20.9M |
自由现金流率AAPGACRS
| Q4 25 | — | -1015.8% | ||
| Q3 25 | — | -332.1% | ||
| Q2 25 | — | -563.5% | ||
| Q1 25 | — | -900.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -446.0% | ||
| Q1 24 | — | -873.6% |
资本支出强度AAPGACRS
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
